Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Lung Cancer

Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, Gori S, Giannarelli D, Novello S, Passiglia F

doi: 10.1016/j.lungcan.2025.108576

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Lung Cancer

Fujisaki T, Miyauchi E, Kida G, Miura Y, Watanabe K, Ashinuma H, Tamiya M, Kikuchi H, Arai D, Takahashi S, Masuda K, Takigami A, Nagai Y, Miyawaki T, Tsubata Y, Nakao A, Masubuchi K, Nishiyama K, Watanabe S, Morita S, Maemondo M

doi: 10.1016/j.lungcan.2025.108597

Lung, Respiratory and Thoracic Cancer

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Lung Cancer

Eklund EA, Orgard M, Wallin D, Sayin SI, Fagman H, Isaksson J, Raghavan S, Akyürek LM, Nyman J, Wiel C, Hallqvist A, Sayin VI

doi: 10.1016/j.lungcan.2025.108573

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy

Eur J Surg Oncol

Abdelnour-Berchtold E, Chriqui LE, Zermatten L, Papadopoulos S, Forster C, Hasenauer A, Bedat B, Zellweger M, Kinj R, Mederos N, Christodoulou M, Addeo A, Triponez F, Karenovics W, Gonzalez M, Krueger T, Peters S, Bouchaab H, Perentes JY

doi: 10.1016/j.ejso.2026.111401

Lung, Respiratory and Thoracic Cancer

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Lung Cancer (Auckl)

Luo FX, Arter Z, Ou SI, Nagasaka M

doi: 10.2147/LCTT.S520833

Lung, Respiratory and Thoracic Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

ELCC 2025

Lung, Respiratory and Thoracic Cancer

Related content

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival

Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy

LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC